# Telitacicept for PGNMID: A Single-Arm Study

> **NCT07111338** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Peking University First Hospital** · enrollment: 10 (estimated)

## Conditions studied

- Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits

## Interventions

- **DRUG:** Telitacicept 160mg

## Key facts

- **NCT ID:** NCT07111338
- **Lead sponsor:** Peking University First Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-07-12
- **Primary completion:** 2027-05-29
- **Final completion:** 2027-05-29
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07111338

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07111338, "Telitacicept for PGNMID: A Single-Arm Study". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT07111338. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*